• Sign up to our Free Newsletter
  • Contact Us
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Editor’s Choice

Biotech Showcase

Protecting and Preserving the Intestinal Microbiome from Antibiotic-induced Dysbiosis with DAV132

February 17, 2022 Jean de Gunzburg

  This presentation was part of the Biotech Showcase at the Pharmabiotic Research Institute’s Annual Event, Pharmabiotics Conference & Partnering. The PRI is Europe’s leading microbiome regulatory science expertise center and was founded in 2010 […]

Editor's Choice

ELIGO v SNIPR: a reflection on IP strategies in a competitive environment

February 7, 2022 Craig Thomson and Jennifer Bailey

Introduction In November 2021, US “Interference” proceedings resulted in cancellation of five US patents owned by SNIPR TECHNOLOGIES. It was concluded that the technology claimed in those patents was invented earlier by The Rockefeller University.  […]

Editor's Choice

Ferring takes pre-emptive action in IP dispute with Finch

February 2, 2022 Kristina Campbell

In the relatively young microbiome biotechnology industry, companies aim to distinguish themselves from a growing number of competitors by protecting their intellectual property (IP). As in any new field, initial patent claims tend to be […]

Editor's Choice

Food for Health: A new direction for American Agriculture

December 14, 2021 Andrew Benson and Bruce German

Over the past two years during this global pandemic, it has become clear that regrettably, those of us who are the most vulnerable to severe disease from SARS-CoV-2 are the ones with underlying chronic diseases […]

Editor's Choice

CRISPRing the microbiome is just around the corner

December 10, 2021 Robert Sanders, UC Berkley

To date, CRISPR enzymes have been used to edit the genomes of one type of cell at a time: They cut, delete or add genes to a specific kind of cell within a tissue or […]

Biotech Showcase

Bringing the Transformative Power of Synthetic Biology to Medicine

December 6, 2021 Aoife Brennan

  This presentation was part of the Biotech Showcase at the Pharmabiotic Research Institute’s Annual Event, Pharmabiotics Conference & Partnering. The PRI is Europe’s leading microbiome regulatory science expertise center and was founded in 2010 […]

Editor's Choice

Eligo Bioscience Announces Successful Outcome in US Patent Interference against SNIPR Biome

December 2, 2021 Microbiome Times

Eligo Bioscience today announced that the US Patent and Trademark Office (USPTO) has issued on Nov 19, 2021, a decision and a judgement acknowledging priority to the invention of precision bacterial killing using CRISPR to […]

Editor's Choice

Microbiome ‘editing’ for infectious disease and more: An overview of bacteriophage drug development

December 1, 2021 Luis Gosálbez

Microbiome-focused drug development is often thought of as the addition of beneficial strains or consortia of bacteria to specific sites in the body. Yet some drug products rather aim to take away elements or profoundly […]

Editor's Choice

Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives

November 23, 2021 Aaron B Cowley and Nicole O'Brien

Live biotherapeutic products (LBPs) are defined by the U.S. FDA as biological products that contain live organisms applicable to the prevention, treatment, or cure of a disease or condition (1). LBP therapies continue to attract […]

Biotech Showcase

Engineering the Microbiome to Treat Skin Diseases

November 16, 2021 Travis Whitfill

  The skin microbiome plays a fundamental role in human health, protecting against pathogens and antigens, while bolstering cutaneous immunity. Imbalances in the skin microbiome (i.e. “dysbiosis”) are highly associated with severity of skin disease, […]

Editor's Choice

Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection

September 30, 2021 Microbiome Times

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced final results of an analysis from five prospective trials of its investigational microbiota-based live biotherapeutic, RBX2660, for the reduction of recurrent C. difficile infection (rCDI). The […]

Posts navigation

« 1 2 3 4 … 11 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • New standards in sensitivity and accuracy for microbiome research
    September 20, 2023
  • Integrating Microbiome and Dietary Data: Microbiome Data Congress 2023
    August 22, 2023
  • Distinguishing Strains in Microbiome Samples: Considerations and Challenges
    July 19, 2023
  • Proven Complementary Effect of Probiotic Yeast and Bacteria
    June 21, 2023
  • Microbiome drug development: Analysis of the historical pipeline reveals promising areas and bottlenecks
    May 25, 2023
sign up

Sign up to the Microbiome Times newsletter